Scott Myers
Chairman at DYNAVAX TECHNOLOGIES CORPORATION
Net worth: 218 894 $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Julia Eastland | F | 59 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | 14 years |
| Ryan Spencer | M | 46 | 19 years | |
| Seth Harmon | M | 45 | 1 years | |
| Stefan Antonsson | M | - |
Ironshore Therapeutics, Inc.
 Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | - |
| Stephanie C. Read | F | 48 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 4 years |
| Luke Walker | M | - | 2 years | |
| Ildiko Mehes | F | - |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 2 years |
| Matthew Bartholomae | M | - | 1 years | |
| Neil Bander | M | - |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
| Andrew Muratore | M | - | 3 years | |
| Metin Kurtoglu | M | 46 | 1 years | |
| Meg Smith | F | - | 5 years | |
| Deborah Baron | F | 55 | 3 years | |
| Peter Paradiso | M | 73 | 4 years | |
| Brent MacGregor | M | 60 | 4 years | |
| Francis Cano | M | 79 | 15 years | |
| Carsten Brunn | M | 53 | 1 years | |
| Caroline Andersson | F | - | 9 years | |
| Philip Kantoff | M | 69 |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | - |
| Kevin Bain | M | 66 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | 2 years |
| David Novack | M | 62 | 11 years | |
| Peggy Phillips | F | 70 | 18 years | |
| Dan Kisner | M | 77 | 14 years | |
| Robert Janssen | M | 70 | 14 years | |
| Aniz Girach | M | 57 | 2 years | |
| Elaine Sun | F | 53 | 3 years | |
| Jean-Christophe Tellier | M | 65 | 13 years | |
| Frank Lanza | M | 62 | 5 years | |
| Alex Oh | M | - | 2 years | |
| Patricia Novy | M | - | 3 years | |
| David Ferguson | M | 72 |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | - |
| James B. Bucher | M | 59 | 1 years | |
| Riccardo Manetti | M | - | 4 years | |
| Jeff P. Coon | M | 61 | 5 years | |
| Sarah Gheuens | M | 45 | 1 years | |
| Todd Lopeman | M | - | 10 years | |
| Dong Yu | M | - | 3 years | |
| John L. Slebir | M | 58 | 3 years | |
| Justin Burgess | M | - | 12 years | |
| Nicole Arndt | F | - | - | |
| Timothy Springer | M | 76 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Arnold Lippa | M | 77 |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 11 years |
| Edward Myles | M | 52 | 4 years | |
| Jonathan Violin | M | 49 | 3 years | |
| Christopher Henney | M | 83 | 13 years | |
| Luke Evnin | M | 60 | 5 years | |
| Jan Skvarka | M | 57 | 2 years | |
| Georgia Erbez | F | 57 | 4 years | |
| Stephen Lau | M | 52 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | - |
| Patrick Baeuerle | M | 66 | 5 years | |
| James Parsons | M | 58 | 10 years | |
| Robert A. Uger | M | 53 | 8 years | |
| Anders Fredrik Williamsson | M | 70 | 7 years | |
| Ron Hunt | M | 59 | 7 years | |
| William Heiden | M | 64 | 8 years | |
| Andrew Hack | M | 50 | 4 years | |
| Nancy Whiting | M | 51 | - | |
| Robert L. Kirkman | M | 75 | 8 years | |
| Gerald McMahon | M | 69 | 5 years | |
| Gino Santini | M | 66 | 8 years | |
| David Johnson | M | 41 | 1 years | |
| Karl Lundström | M | 62 | 2 years | |
| Norman J. Ornstein | M | - | - | |
| Helena Tayton-Martin | M | 57 | 4 years | |
| Scott A. Beardsley | M | 56 | 4 years | |
| Carl-Johan Blomberg | M | 72 | 2 years | |
| Anne Phillips | M | 70 | 1 years | |
| Henrik Juuel | M | 59 | 5 years | |
| Joseph Vittiglio | M | 52 | 5 years | |
| Bill Silbey | M | 65 | - | |
| Penka Petrova | M | 56 | 8 years | |
| Rosemary Harrison | M | 41 | 1 years | |
| Mohammed Khoso Baluch | M | 66 | 8 years | |
| Robert Perez | M | 59 | 11 years | |
| Kristian Humer | M | 49 | 2 years | |
| Kathrine O'Brien | F | 61 | 1 years | |
| Armand de Decker | M | - | - | |
| Thomas Leysen | M | 63 | 3 years | |
| Nunzio Antonelli | M | - | - | |
| Alf Gunnar Martin Nicklasson | M | 69 | 8 years | |
| Richard L. Jackson | M | 84 | 14 years | |
| Davey Scoon | M | 78 | 14 years | |
| Mark McDade | M | 69 | 8 years | |
| Maria Christina Schauman | F | 59 | 8 years | |
| James Sulat | M | 73 | 6 years | |
| Michael Kamarck | M | 73 | 1 years | |
| Barbara H. Deptula | F | 69 | 7 years | |
| Paolo Pucci | M | 63 | 1 years | |
| John Fallon | M | 76 | 6 years | |
| Thomas Fulton Wilson McKillop | M | 81 | 7 years | |
| Paul R. Fonteyne | M | 63 | 1 years | |
| Luke Beshar | M | 65 | 7 years | |
| Albrecht de Graeve | M | 69 | 14 years | |
| Linda S. Lennox | F | 59 | 5 years | |
| Todd James | M | - | 1 years | |
| Paul Walker | M | 49 | 1 years | |
| Fabrice Enderlin | M | - | 9 years | |
| Thomas Reynolds | M | 65 | 7 years | |
| Jean-Pierre Kinet | M | 70 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 55 | 55.56% |
| Canada | 19 | 19.19% |
| Belgium | 12 | 12.12% |
| Sweden | 8 | 8.08% |
| France | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Scott Myers
- Personal Network
